Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Choroidal Neovascularization Choroid Diseases Eye Diseases Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Uveal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

active choroidal neovascularization

Exclusion criteria

pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Treatment and study plan

ranibizumab

Drug

0.5mg intravitreal injection

Primary outcomes

The primary outcome measures for safety and tolerability

Time frame: Mean change in visual acuity from baseline to 6 months & 12 months

Secondary outcomes

The secondary outcome measures for efficacy

Time frame: Mean change in visual acuity from baseline to 6 & 12 months. Change in retinal thickness from baseline to week 1, month 1, 2, 3, 6, & 12 measured by OCT. Change in area of CNV from baseline to month 3, 6 & 12 measured by FA

Sponsors and collaborators

Lead sponsor

Ophthalmic Consultants of Boston

Other

Collaborators

Genentech, Inc.

Registry information

Official study title

A Single Center Study of the Safety and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects With CNV Secondary to Causes Other Than AMD.

Important dates

Study start: 2005
Primary completion: 2009
Study completion: 2009
First posted: Nov 3, 2006
Registry last updated: Jan 8, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed